RADical response puts an exceptional responder in CHKmate: A synthetic lethal curative response to DNA-Damaging chemotherapy?

Guang Peng, Scott E. Woodman, Gordon B. Mills

    Research output: Contribution to journalArticle

    2 Scopus citations


    In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.

    Original languageEnglish (US)
    Pages (from-to)988-990
    Number of pages3
    JournalCancer discovery
    Issue number9
    StatePublished - Sep 2014


    ASJC Scopus subject areas

    • Oncology

    Cite this